Evolving Treatment Paradigms

FIRAZYR is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.

Clinical practice recommendations for HAE management

In 2012, guidelines from two international associations — the Hereditary Angioedema International Working Group (HAWK) and the World Allergy Organization (WAO) — were published, outlining their recommendations for the treatment of hereditary angioedema (HAE) attacks.1

Both guidelines were developed by international HAE experts, and only physicians who were responsible for treatment prescription were allowed to vote on the recommendations.1

In 2013, guidelines from the US Hereditary Angioedema Association (HAEA) Medical Advisory Board were also published, outlining their recommendations for the treatment of HAE.2

Several on-demand and prophylactic therapies are described in the literature.

Multiple therapies have been recommended, and no one product has been endorsed. FIRAZYR is one option for the treatment of acute HAE attacks.

WAO/EAACI: International guidelines for the management of hereditary angioedema3

The 2017 revision and update

Select recommendations in the guidelines include:

  • All attacks should be considered for on-demand treatment, especially any attack affecting or potentially affecting the upper airway. (recommendation 2)
  • All patients should have an action plan and treat attacks as early as possible. (recommendations 3 and 16)
  • All patients should have sufficient medication for on-demand treatment of two attacks, or at least two doses, and carry on-demand medication at all times. (recommendation 6)
  • All patients who are provided with on-demand treatment licensed for self-administration should be taught to self-administer. (recommendation 18)
  • Patients should be evaluated for long-term preventive treatment at every doctor's visit, or at least once a year. (recommendation 9)

HAEA: Recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency2

Select recommendations in the guidelines include:

  • All patients with HAE due to C1INH deficiency should have access to at least 2 standard doses of on-demand treatment.
  • All attacks, regardless of location, should be considered for treatment as soon as they are clearly recognized.
  • To be most effective, on-demand treatment of attacks should be administered early in the attack.

HAWK: Evidence-based treatment guidelines that support a proactive, patient-centric approach to HAE treatment1

Select recommendations in the guidelines include:

  • All attacks, regardless of location, are eligible for treatment as soon as they are clearly recognized by the patient. (recommendation 11)
  • On-demand treatment for acute attacks should be the initial goal of therapy for all patients. (recommendation 13)
  • Whenever possible and allowed by drug-specific summary product characteristics, patients should have an on-demand treatment medicine to treat acute attacks at home and should be trained to self-administer these medicines. (recommendation 10)